lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Only at some distance does convection occur to carry heat to the bulb's envelope. The orientation of the filament influences efficiency. Gas flow parallel to the filament, e.g., a vertically oriented bulb with vertical (or axial) filament, reduces convective losses. The efficiency of the lamp increases with a larger filament diameter. Thin-filament, low-power bulbs benefit less from a fill gas, so are often only evacuated. Early light bulbs with carbon filaments also used carbon monoxide, nitrogen, or mercury vapor. However, carbon filaments operate at lower temperatures than tungsten ones, so the effect of the fill gas was not significant as the heat losses offset any benefits.
Protein deficiency and malnutrition (PEM) can lead to a variety of ailments, including intellectual disability and kwashiorkor. Symptoms of kwashiorkor include apathy, diarrhea, inactivity, failure to grow, flaky skin, fatty liver, and edema of the belly and legs. This edema is explained by the action of lipoxygenase on arachidonic acid to form leukotrienes and the normal functioning of proteins in fluid balance and lipoprotein transport. PEM is fairly common worldwide in both children and adults and accounts for 6 million deaths annually. In the industrialized world, PEM is predominantly seen in hospitals, is associated with disease, or is often found in the elderly.
=== Campaigning === Heseltine was not one to befriend and gossip with colleagues or backbenchers. He did not regard this as an insurmountable problem, as neither Heath nor Thatcher had been particularly "clubbable" either. From about the mid-1970s, he began a campaign of addressing local associations, sometimes using a helicopter to speak to several in one day. Heseltine had often had a reputation for being very cold and aloof with backbench MPs and party activists (Steven Norris said that after a visit to his constituency in 1983, local activists used a poster of Heseltine as a dartboard). However, in 1986–1990 he was a frequent visitor to local constituency dinners, although he usually attacked Labour rather than the Conservative government, and he used his wealth to afford a chauffeur and a helicopter. Heseltine campaigned in 100 constituencies in the 1987 election, attracting more publicity than many Cabinet ministers, although seldom mentioning Thatcher by name. During this period Heseltine enjoyed excellent relations with the media: among TV journalists he was in regular touch with Elinor Goodman of Channel 4 News (herself a former Haymarket employee), James Mates of ITN (son of his lieutenant Michael Mates) and John Cole, whilst among print journalists he was close to his old friend Anthony Howard (Deputy Editor of the Observer), Peter Jenkins, and especially close to Anthony Bevins of The Independent and the young Alastair Campbell of the Daily Mirror.
Sources: en.wikipedia.org
Crystallization of ubiquitin protein was successfully done using racemic crystallography. Crystallization of either D-ubiquitin or L-ubiquitin alone is difficult, whereas a racemic mixture of D-ubiquitin and L-ubiquitin was readily crystallized and diffraction quality crystals were obtained overnight in almost half the conditions tested in a standard commercial crystallization screen. Crystallization of racemates of disulfide-containing microprotein molecules was used to determine the structure of trypsin inhibitor SFTI-1 (14 amino acids,1 disulfide), conotoxin cVc1.1 (22 amino acids, 2 disul-fides) and cyclotide kB1 (29 amino acids, 3 disulfides). Using X-ray diffraction, it was found that the racemates crystallized in the centrosymmetric spacegroups P3(bar), Pbca and P1(bar). Interestingly, achiral "'peptoid'" chains were found to fold as racemic pairs and crystallize in highly preferred centrosymmetric space groups. A high-resolution crystal structure of the racemate of a heterochiral D-protein complex with vascular endothelial growth factor A (VEGF-A). The mirror image D-protein form of VEGF-A was used in phage display to identify a 56 residue L-protein binder with nanomolar affinity; the chemically synthesized D-protein binder had the same affinity for the L-protein form of VEGF-A. A mixture of chemically synthesized proteins consisting of D-VEGF-A, L-VEGF-A, and two equivalents each of the D-protein binder and L-protein binder, gave racemic crystals in the centrosymmetric space group P21/n.
An interesting remaining piece of Nazi architecture can be found in the former Berlin Tempelhof Airport which closed all airport operations in 2008. The main terminal was designed and built during the late 1930s and early 1940s according to a design by Ernst Sagebiel following the ideas of Speer and Hitler including that of ruin value. It was designed to be the main hub for Hitler's redesigned Berlin, to be called Germania. When completed, it was the world's largest building and today, should the building fall into disrepair, Speer and Hitler's ruin value theory may be demonstrated.
drugs that also prolong the QT interval because of potential problems with the heart rhythm ergot alkaloids statins triazolam and oral midazolam sulfonamides with a potential to cause hypoglycaemia (low blood sugar)
=== Examples of intraarticular fractures === Bennett's Fracture intraarticular fracture of the base of the first metacarpal Rolando Fracture comminuted intraarticular fracture of the base of the first metacarpal Calcaneal Fracture fracture of the calcaneus that may extend into the subtalar joint Tibial Plateau Fracture fracture of the proximal portion of the tibia that may extend into the knee joint Pilon Fracture fracture of the distal articular surface of the tibia Distal Radius Fracture fracture of the distal portion of the radius that may extend into the wrist joint Olecranon Fracture fracture of the olecranon process of the ulna at the elbow Femoral Head Fracture fracture of the head of the femur that may extend into the hip joint Some of these fractures such as a Bennett's or Rolando fracture are coined based on their intraarticular involvement, while others such as femoral head fractures, tibial plateau fractures, and distal radius fractures may or may not extend into the joint.
Sources: en.wikipedia.org
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. GIP-R is a member of the class B family of G protein–coupled receptors. GIP-R is found on beta-cells in the pancreas, where it serves as the receptor for the gastric inhibitory polypeptide (GIP).
== Research == Cuatrecasas is known for the invention and development of affinity chromatography, a process utilized within the Aethlon HemopurifierTM. He was involved in the discovery, development and marketing registration of more than forty medicines. Some of those medicines include: zidovudine (AZT, AIDS), acyclovir (Zovirax, anti-herpes), permethrin (Rid, head and body lice), bupropion (Wellbutrin, antidepressant), colfosceril palmitate (Exosurf, infant acute respiratory distress), remifentanil (Ultiva, analgesic/anesthetic), sumatriptan (Imigran, migraine), salmeterol (Serement, asthma), tacrine (Cognex, Alzheimers), gabapentin (Neurontin, epilepsy and neuropathic pain), troglitazone (Rezulin, diabetes), and atorvastatin (Lipitor, cholesterol lowering). In 1987, Cuatrecasas was awarded the Wolf Prize in Medicine in 1987 along with Meir Wilchek "for the invention and development of affinity chromatography and its applications to biomedical sciences."
Wawrik, B; Paul, JH; Tabita, FR (2002). "Real-time PCR quantification of rbcL (ribulose-1,5-bisphosphate carboxylase/oxygenase) mRNA in diatoms and pelagophytes". Appl. Environ. Microbiol. 68 (8): 3771–3779. Bibcode:2002ApEnM..68.3771W. doi:10.1128/aem.68.8.3771-3779.2002. PMC 123995. PMID 12147471. Logan J; Edwards K; Saunders N, eds. (2009). Real-Time PCR: Current Technology and Applications. Caister Academic Press. ISBN 978-1-904455-39-4.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.